Research programme - STING TLR9 agonist conjugate - CS Bay Therapeutics
Latest Information Update: 08 Aug 2022
At a glance
- Originator CS-Bay Therapeutics
- Class Antineoplastics; Drug conjugates
- Mechanism of Action MPYS protein stimulants; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Jun 2022 Pharmacodynamics data from preclinical trial in Cancer released by CS Bay Therapeutics
- 28 Jun 2022 CS Bay Therapeutics plans to submit Investigational New Drug (IND) application for phase I trial in Cancer in 1Q 2023 (CS Bay Therapeutics pipeline, June 2022)
- 28 Jun 2022 Preclinical trials in Cancer in USA (SC) (CS Bay Therapeutics pipeline, June 2022)